All Oncology News

EPCORE FL-1 showed that epcoritamab/lenalidomide/rituximab yielded superior efficacy vs lenalidomide/rituximab across follicular lymphoma populations.

Azacitidine plus venetoclax and ivosidenib produced robust responses and induced high rates of MRD negativity in IDH1-mutated newly diagnosed AML.

Baseline ctDNA positivity was associated with inferior DFS regardless of treatment arm in the phase 3 KEYNOTE-564 trial.

Alexander Kutikov, MD, FACS, discusses the role of focal therapy in RCC management.

The in vivo CAR T-cell therapy KLN-1010 produced deep MRD-negative responses in relapsed/refractory multiple myeloma.

Real-world data showed zanubrutinib was associated with longer time to next treatment and improved overall survival vs acalabrutinib in treatment-naive CLL.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

The research offers an early view into challenges that health systems across the globe will likely face as extreme heat becomes more common.

The FDA has accepted for review an sBLA for adjuvant atezolizumab plus chemotherapy in stage III dMMR/MSI-H colon cancer.

Marwan G. Fakih, MD, discusses how updated OS data from POD1UM-303 cement frontline retifanlimab plus chemotherapy as the standard of care in advanced SCAC.

Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.

Megan Kruse, MD, discusses CDK4/6 inhibitor decision-making for patients with HR-positive breast cancer and future directions for oral SERD and ADC use.

Sonrotoclax plus zanubrutinib drove durable remissions across IGHV-mutated and del(17p)/TP53 CLL subgroups in an updated phase 1/1b analysis.

Pavlos Msaouel, MD, PhD, discusses a study of panitumumab-based EGFR blockade in SMARCB1-deficient RMC.

FDA approved generic gallium Ga 68 gozetotide injection for PET imaging of PSMA-positive lesions in prostate cancer.

The Yawkey Foundation made a $50 million grant to support Dana-Farber's planned cancer hospital and the Future of Cancer Care Fund.

Oncology experts provide commentary on the meeting's biggest and most impactful presentations across the GI cancer continuum.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

New spatial atlas of immune cell structures reveals how key features vary across tumor types and influence patient outcomes.

Lack of a statistically significant PFS improvement and improbability of achieving OS benefit led to the discontinuation of the KEYNOTE-D46/EVOKE-03 trial in PD-L1–high NSCLC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

The EU has approved the use of subcutaneous isatuximab delivered via OBI across all existing indications for IV isatuximab for multiple myeloma.

Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer.

City of Hope’s data-driven model integrates survivorship care from diagnosis through decades of follow-up.

Experts share the key myeloproliferative neoplasm and acute myeloid leukemia presentations they’re anticipating at the 2026 EHA Congress.

In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.

Experts highlight some of the top hematologic oncology data presented at ASCO 2026, including key studies in multiple myeloma and diffuse large B-cell lymphoma.

Aglatimagene besadenovec plus ERBT displayed an accumulating benefit in high-risk prostate cancer after extended follow-up.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.